This week, we have conversations with Sean MacDonald, CEO of Domain Therapeutics, Carina Kern, CEO and founder of LinkGevity, and Nadia Harhen, general manager of AI Simulation at SandboxAQ.

Interview times:

03:41 Domain Therapeutics

27:14 SandboxAQ

48:04 LinkGevity

Domain Therapeutics

Domain Therapeutics is delivering breakthrough GPCR-targeting therapies in immuno-oncology and inflammation.

Domain recently shared first-in-human results for EP4 antagonist DT-9081 (tumour-growth inhibition + clear RP2D), new pre-clinical detail on Treg-depleting anti-CCR8 mAb DT-7012, and breakthrough findings showing their PAR2 biased NAM can re-programme macroph ...